| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |